Obesity and outcome in pediatric acute lymphoblastic leukemia.
暂无分享,去创建一个
A. Bleyer | H. Sather | B. Lange | M. Trigg | P. Gaynon | W. Carroll | F. Dorey | J. Franklin | A. Butturini | S. Siegel | W. Bleyer | C. Fu | N. Seibel | P. Rogers | David W Henry | David Henry
[1] M. Vignetti,et al. Obesity Independently Predicts Event Free Survival (EFS) in Adults with BCR-ABL-Negative Acute Lymphoblastic Leukemia (ALL). A Retrospective Analysis of Two GIMEMA Studies. , 2005 .
[2] R. Gelber,et al. Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index , 2005, The Lancet.
[3] A. Boddy,et al. Pharmacokinetics of Dactinomycin in a Pediatric Patient Population: a United Kingdom Children's Cancer Study Group Study , 2005, Clinical Cancer Research.
[4] D. Wypij,et al. Impact of body composition on pharmacokinetics of doxorubicin in pediatric patients: A Glaser Pediatric Research Network study , 2005 .
[5] M. Matsuda,et al. Visfatin: A Protein Secreted by Visceral Fat That Mimics the Effects of Insulin , 2005, Science.
[6] Todd A Alonzo,et al. Mortality in overweight and underweight children with acute myeloid leukemia. , 2005, JAMA.
[7] Morihiro Matsuda,et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. , 2004, The Journal of clinical investigation.
[8] E. Calle,et al. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms , 2004, Nature Reviews Cancer.
[9] K. Flegal,et al. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. , 2004, JAMA.
[10] M. Konopleva,et al. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate–cytarabine regimen , 2004, Cancer.
[11] S. Kihara,et al. Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[12] J. Meyerhardt,et al. Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] J. Bub,et al. Prostate Cancer Cell-Adipocyte Interaction , 2003, Journal of Biological Chemistry.
[14] W. Carroll. Race and outcome in childhood acute lymphoblastic leukemia. , 2003, JAMA.
[15] Nancy F Krebs,et al. Prevention of pediatric overweight and obesity. , 2003, Pediatrics.
[16] W. Aronson,et al. Insulin-like growth factor I (IGF-I) and IGF binding protein-1 modulate prostate cancer cell growth and apoptosis: possible mediators for the effects of diet and exercise on cancer cell survival. , 2003, Endocrinology.
[17] N. Heerema,et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. , 2003, Blood.
[18] N. Heerema,et al. Intensification of therapy for children with lower-risk acute lymphoblastic leukemia: long-term follow-up of patients treated on Children's Cancer Group Trial 1881. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] S. Jhanwar,et al. Human Granulocyte Colony-Stimulating Factor in Children With High-Risk Acute Lymphoblastic Leukemia: A Children’s Cancer Group Study , 2003 .
[20] P. Roach,et al. Nutrient-Regulated Protein Kinases in Budding Yeast , 2002, Cell.
[21] N. Heerema,et al. Double-delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. , 2002, Blood.
[22] M. Vignetti,et al. Obesity and autologous stem cell transplantation in acute myeloid leukemia , 2001, Bone Marrow Transplantation.
[23] D. Stram,et al. Duration of hospitalization as a measure of cost on Children's Cancer Group acute lymphoblastic leukemia studies. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] G. Cheymol. Effects of Obesity on Pharmacokinetics , 2000 .
[25] H. Sather,et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. , 1998, The New England journal of medicine.
[26] H. Sather,et al. Response of children with high-risk acute lymphoblastic leukemia treated with and without cranial irradiation: a report from the Children's Cancer Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] F. Dunstan,et al. The validity of body mass index for the assessment of adiposity in children with disease states. , 1997, Annals of human biology.
[28] B. Hoffman,et al. Fasting Insulin and Outcome in Early-Stage Breast Cancer: Results of a Prospective Cohort Study , 2002 .
[29] S. Guandalini,et al. Fat body mass and pharmacokinetics of oral 6-mercaptopurine in children with acute lymphoblastic leukemia. , 1991, Therapeutic drug monitoring.